G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)

PHASE1CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

July 2, 2009

Primary Completion Date

April 1, 2013

Study Completion Date

April 1, 2013

Conditions
Malaria
Interventions
DRUG

Chloroquine

The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.

DRUG

Primaquine

Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment

DRUG

Tafenoquine

Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria

Trial Locations (2)

10700

GSK Investigational Site, Bangkok

63110

GSK Investigational Site, Tak

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

lead

GlaxoSmithKline

INDUSTRY